Comparing approaches to the management of malignant pleural effusions

References

• Porcel JM, Esquerda A, Vives M, et al. Etiology of pleural effusions: analysis of more than 3,000 consecutive thoracenteses. Arch Bronconeumol. 2014;50(5):161–165.
   PubMed Web of Science ®Google Scholar
• Segal A, Sterrett GF, Frost FA, et al. A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20-year audit. Pathology. 2013;45(1):44–48.
   PubMed Web of Science ®Google Scholar
• Porcel JM, Gasol A, Bielsa S, et al. Clinical features and survival of lung cancer patients with pleural effusions. Respirology. 2015;20(4):654–659.
   PubMed Web of Science ®Google Scholar
• Hirata T, Yonemori K, Hirakawa A, et al. Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients. Eur Respir J. 2011;38(6):1425–1430.
   PubMed Web of Science ®Google Scholar
• Beckett P, Edwards J, Fennell D, et al. Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales. Lung Cancer. 2015;88(3):344–348.
   PubMed Web of Science ®Google Scholar
• Clive AO, Kahan BC, Hooper CE, et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 2014;69(12):1098–1104.
   PubMed Web of Science ®Google Scholar
• Fysh ET, Bielsa S, Budgeon CA, et al. Predictors of clinical use of pleurodesis and/or indwelling pleural catheter therapy for malignant pleural effusion. Chest. 2015;147(6):1629–1634.
   PubMed Web of Science ®Google Scholar
• Psallidas I, Kalomenidis I, Porcel JM, et al. Malignant pleural effusion: from bench to bedside. Eur Respir Rev. 2016;25(140):189–198.
   PubMed Web of Science ®Google Scholar
• Light RW. Pleural diseases. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2013.
   Google Scholar
• Davies HE, Gary Lee YC. Pleurodesis. In: Light RW, Gary Lee YC, eds. Textbook of pleural diseases. 3rd ed. Boca Raton: CRC Press; 2016. p. 553–569.
   Google Scholar
• Rahman NM, Pepperell J, Rehal S, et al. Effect of opioids vs NSAIDs and larger vs smaller chest tube size on pain control and pleurodesis efficacy among patients with malignant pleural effusion: the TIME1 randomized clinical trial. Jama. 2015;314(24):2641–2653.
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. Management of malignant pleural effusions. Am J Respir Crit Care Med. 2000;162(5):1987–2001.
   PubMed Web of Science ®Google Scholar
• Loddenkemper R, Mathur PN, Noppen M, et al., eds. Medical thoracoscopy/pleuroscopy: manual and atlas. Stuttgart: Thieme; 2011.
   Google Scholar
• Clive AO, Jones HE, Bhatnagar R, et al. Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst Rev. 2016 May;8(5):CD010529.
   Google Scholar
• Xia H, Wang XJ, Zhou Q, et al. Efficacy and safety of talc pleurodesis for malignant pleural effusion: a meta-nalysis. Plos One. 2014;9(1):e87060.
   PubMed Web of Science ®Google Scholar
• Chen J, Li Z, Xu N, et al. Efficacy of medical thoracoscopic talc pleurodesis in malignant pleural effusion caused by different types of tumors and different pathological classifications of lung cancer. Int J Clin Exp Med. 2015;8(10):18945–18953.
   PubMed Web of Science ®Google Scholar
• Bielsa S, Hernández P, Rodriguez-Panadero F, et al. Tumor type influences the effectiveness of pleurodesis in malignant effusions. Lung. 2011;189(2):151–155.
   PubMed Web of Science ®Google Scholar
• Mummadi S, Kumbam A, Hahn PY. Malignant pleural effusions and the role of talc poudrage and talc slurry: a systematic review and meta-analysis. Version 2. F1000Res. 2015;3:254.
   Google Scholar
• Arellano-Orden E, Romero-Falcon A, Juan JM, et al. Small particle-size talc is associated with poor outcome and increased inflammation in thoracoscopic pleurodesis. Respiration. 2013;86(3):201–209.
   PubMed Web of Science ®Google Scholar
• Lee YC, Baumann MH, Maskell NA, et al. Pleurodesis practice for malignant pleural effusions in five English-speaking countries: survey of pulmonologists. Chest. 2003;124(6):2229–2238.
   PubMed Web of Science ®Google Scholar
• Bilaceroglu S, Guo Y, Hawthorne ML, et al. Oral forms of tetracycline and doxycycline are effective in producing pleurodesis. Chest. 2005;128(5):3750–3756.
   PubMed Web of Science ®Google Scholar
• Emad A, Rezaian GR. Treatment of malignant pleural effusions with a combination of bleomycin and tetracycline. A comparison of bleomycin or tetracycline alone versus a combination of bleomycin and tetracycline. Cancer. 1996;78(12):2498–2501.
   PubMed Web of Science ®Google Scholar
• Martínez-Moragón E, Aparicio J, Rogado MC, et al. Pleurodesis in malignant pleural effusions: a randomized study of tetracycline versus bleomycin. Eur Respir J. 1997;10(10):2380–2383.
   PubMed Web of Science ®Google Scholar
• Sartori S, Tassinari D, Ceccotti P, et al. Prospective randomized trial of intrapleural bleomycin versus interferon alfa-2b via ultrasound-guided small-bore chest tube in the palliative treatment of malignant pleural effusions. J Clin Oncol. 2004;22(7):1228–1233.
   PubMed Web of Science ®Google Scholar
• Alavi AA, Eshraghi M, Rahim MB, et al. Povidone-iodine and bleomycin in the management of malignant pleural effusion. Acta Med Iran. 2011;49(9):584–587.
   PubMedGoogle Scholar
• Bucknor A, Harrison-Phipps K, Davies T, et al. Is silver nitrate an effective means of pleurodesis? Interact Cardiovasc Thorac Surg. 2015;21(4):521–525.
   PubMed Web of Science ®Google Scholar
• Terra RM, Bellato RT, Teixeira LR, et al. Safety and systemic consequences of pleurodesis with three different doses of silver nitrate in patients with malignant pleural effusion. Respiration. 2015;89(4):276–283.
   PubMed Web of Science ®Google Scholar
• Paschoalini Mda S, Vargas FS, Marchi E, et al. Prospective randomized trial of silver nitrate vs talc slurry in pleurodesis for symptomatic malignant pleural effusions. Chest. 2005;128(2):684–689.
   PubMed Web of Science ®Google Scholar
• Guo Y, Tang K, Bilaceroglu S, et al. Iodopovidone is as effective as doxycycline in producing pleurodesis in rabbits. Respirology. 2010;15(1):119–125.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Aggarwal AN, Gupta D. Efficacy and safety of iodopovidone pleurodesis through tube thoracostomy. Respirology. 2006;11(1):105–108.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Paul AS, Aggarwal AN, et al. A randomized controlled trial of the efficacy of cosmetic talc compared with iodopovidone for chemical pleurodesis. Respirology. 2011;16(7):1064–1069.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Khan A, Aggarwal AN, et al. Efficacy & safety of iodopovidone pleurodesis: a systematic review & meta-analysis. Indian J Med Res. 2012;135:297–304.
   PubMed Web of Science ®Google Scholar
• Mohsen TA, Zeid AA, Meshref M, et al. Local iodine pleurodesis versus thoracoscopic talc insufflation in recurrent malignant pleural effusion: a prospective randomized control trial. Eur J Cardiothorac Surg. 2011;40(2):282–286.
   PubMed Web of Science ®Google Scholar
• Wagenfeld L, Zeitz O, Richard G. Visual loss after povidone-iodine pleurodesis. N Engl J Med. 2007;357(12):1264–1265.
   PubMed Web of Science ®Google Scholar
• Neto JD, De Oliveira SF, Vianna SP, et al. Efficacy and safety of iodopovidone pleurodesis in malignant pleural effusions. Respirology. 2010;15(1):115–118.
   PubMed Web of Science ®Google Scholar
• Dikensoy O, Light RW. Alternative widely available, inexpensive agents for pleurodesis. Curr Opin Pulm Med. 2005;11(4):340–344.
   PubMed Web of Science ®Google Scholar
• Webb HE, Oaten SW, Pike CP. Treatment of malignant ascitic and pleural effusion with Corynebacterium parvum. Br Med J. 1978;1(6109):338–340.
   PubMed Web of Science ®Google Scholar
• Walker-Renard PB, Vaughan LM, Sahn SA. Chemical pleurodesis for malignant pleural effusions. Ann Intern Med. 1994;120(1):56–64.
   PubMed Web of Science ®Google Scholar
• Nohara K, Takada K, Kojima E, et al. A propensity score-matched comparison of the efficacies of OK-432 and talc slurry for pleurodesis for malignant pleural effusion induced by lung adenocarcinoma. Respir Investig. 2016;54(5):341–346.
   PubMed Web of Science ®Google Scholar
• Ren S, Terman DS, Bohach G, et al. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer. Chest. 2004;126(5):1529–1539.
   PubMed Web of Science ®Google Scholar
• Sartori S, Tassinari D, Ceccotti P, et al. Prospective randomized trial of intrapleural bleomycin versus interferon alfa-2b via ultrasound-guided small-bore chest tube in the palliative treatment of malignant pleural effusions. J Clin Oncol. 2004;22(7):1228–1233.
   PubMed Web of Science ®Google Scholar
• North SA, Au HJ, Halls SB, et al. A randomized, phase III, double-blind, placebo-controlled trial of intrapleural instillation of methylprednisolone acetate in the management of malignant pleural effusion. Chest. 2003;123(3):822–827.
   PubMed Web of Science ®Google Scholar
• Gaafar R, Abdel Rahman AR, Aboulkasem F, et al. Mistletoe preparation (Viscum Fraxini-2) as palliative treatment for malignant pleural effusion: a feasibility study with comparison to bleomycin. Ecancermedicalscience. 2014;8:424.
   PubMedGoogle Scholar
• Cho SJ, Kim SW, Chang JW. Acute pneumonitis consequent on pleurodesis with Viscum album extract: severe chest images but benign clinical course. Multidiscip Respir Med. 2014;9(1):61.
   PubMedGoogle Scholar
• Droghetti A, Vannucci J, Bufalari A, et al. Pleurodesis with thulium cyber laser versus talc poudrage: a comparative experimental study. Lasers Med Sci. 2016;31(7):1407–1413.
   PubMed Web of Science ®Google Scholar
• Dresler CM, Olak J, Herndon JE 2nd, et al. Cooperative Groups Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; North Central Cooperative Oncology Group; Radiation Therapy Oncology Group; Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest. 2005;127(3): 909–915.
   PubMed Web of Science ®Google Scholar
• Fysh ET, Tan SK, Read CA, et al. Pleurodesis outcome in malignant pleural mesothelioma. Thorax. 2013;68(6):594–596.
   PubMed Web of Science ®Google Scholar
• McCann FJ, Chapman SJ, Yu WC, et al. Ability of procalcitonin to discriminate infection from non-infective inflammation using two pleural disease settings. Plos One. 2012;7(12):e49894.
   PubMed Web of Science ®Google Scholar
• Azzopardi M, Porcel JM, Koegelenberg CF, et al. Current controversies in the management of malignant pleural effusions. Semin Respir Crit Care Med. 2014;35(6):723–731.
   PubMed Web of Science ®Google Scholar
• Tobin CL, Thomas R, Chai SM, et al. Histopathology of removed indwelling pleural catheters from patients with malignant pleural diseases. Respirology. 2016;21(5):939–942.
   PubMed Web of Science ®Google Scholar
• Thomas R, Budgeon CA, Kuok YJ, et al. Catheter tract metastasis associated with indwelling pleural catheters. Chest. 2014;146(3):557–562.
   PubMed Web of Science ®Google Scholar
• Tremblay A, Mason C, Michaud G. Use of tunnelled catheters for malignant pleural effusions in patients fit for pleurodesis. Eur Respir J. 2007;30(4):759–762.
   PubMed Web of Science ®Google Scholar
• Lui MM, Fitzgerald DB, Lee YC. Phenotyping malignant pleural effusions. Curr Opin Pulm Med. 2016;22(4):350–355.
   PubMed Web of Science ®Google Scholar
• Lui MM, Thomas R, Lee YC. Complications of indwelling pleural catheter use and their management. BMJ Open Respir Res. 2016;3(1):e000123.
   PubMed Web of Science ®Google Scholar
• Davies HE, Mishra EK, Kahan BC, et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. Jama. 2012;307(22):2383–2389.
   PubMed Web of Science ®Google Scholar
• Putnam JB Jr, Light RW, Rodriguez RM, et al. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer. 1999;86(10):1992–1999.
   PubMed Web of Science ®Google Scholar
• Fysh ET, Waterer GW, Kendall PA, et al. Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion. Chest. 2012;142(2):394–400.
   PubMed Web of Science ®Google Scholar
• Hunt BM, Farivar AS, Vallières E, et al. Thoracoscopic talc versus tunneled pleural catheters for palliation of malignant pleural effusions. Ann Thorac Surg. 2012;94(4):1053–1059.
   PubMed Web of Science ®Google Scholar
• Ost DE, Jimenez CA, Lei X, et al. Quality-adjusted survival following treatment of malignant pleural effusions with indwelling pleural catheters. Chest. 2014;145(6):1347–1356.
   PubMed Web of Science ®Google Scholar
• Warren WH, Kalimi R, Khodadadian LM, et al. Management of malignant pleural effusions using the Pleur(x) catheter. Ann Thorac Surg. 2008;85(3):1049–1055.
   PubMed Web of Science ®Google Scholar
• Wrightson JM, Fysh E, Maskell NA, et al. Risk reduction in pleural procedures: sonography, simulation and supervision. Curr Opin Pulm Med. 2010;16(4):340–350.
   PubMed Web of Science ®Google Scholar
• Fysh ET, Tremblay A, Feller-Kopman D, et al. Clinical outcomes of indwelling pleural catheter-related pleural infections: an international multicenter study. Chest. 2013;144(5):1597–1602.
   PubMed Web of Science ®Google Scholar
• Gilbert CR, Lee HJ, Skalski JH, et al. The use of indwelling tunneled pleural catheters for recurrent pleural effusions in patients with hematologic malignancies: a multicenter study. Chest. 2015;148(3):752–758.
   PubMed Web of Science ®Google Scholar
• Mekhaiel E, Kashyap R, Mullon JJ, et al. Infections associated with tunnelled indwelling pleural catheters in patients undergoing chemotherapy. J Bronchology Interv Pulmonol. 2013;20(4):299–303.
   PubMedGoogle Scholar
• Morel A, Mishra E, Medley L, et al. Chemotherapy should not be withheld from patients with an indwelling pleural catheter for malignant pleural effusion. Thorax. 2011;66(5):448–449.
   PubMed Web of Science ®Google Scholar
• Thomas R, Budgeon CA, Kuok YJ, et al. Catheter tract metastasis associated with indwelling pleural catheters. Chest. 2014;146(3):557–562.
   PubMed Web of Science ®Google Scholar
• Thomas R, Piccolo F, Miller D, et al. Intrapleural fibrinolysis for the treatment of indwelling pleural catheter-related symptomatic loculations: a multicenter observational study. Chest. 2015;148(3):746–751.
   PubMed Web of Science ®Google Scholar
• Fysh ET, Wrightson JM, Lee YC, et al. Fractured indwelling pleural catheters. Chest. 2012;141(4):1090–1094.
   PubMed Web of Science ®Google Scholar
• Puri V, Pyrdeck TL, Crabtree TD, et al. Treatment of malignant pleural effusion: a cost-effectiveness analysis. Ann Thorac Surg. 2012;94(2):374–379.
   PubMed Web of Science ®Google Scholar
• Boshuizen RC, Onderwater S, Burgers SJ, et al. The use of indwelling pleural catheters for the management of malignant pleural effusion-direct costs in a Dutch hospital. Respiration. 2013;86(3):224–228.
   PubMed Web of Science ®Google Scholar
• Villanueva AG. Management of malignant pleural effusions. In: Ernst A, Herth FJF, eds. Principles and practice of interventional pulmonology. New York: Springer; 2013. p. 665–674.
   Google Scholar
• Reddy C, Ernst A, Lamb C, et al. Rapid pleurodesis for malignant pleural effusions: a pilot study. Chest. 2011;139(6):1419–1423.
   PubMed Web of Science ®Google Scholar
• Van Meter MEM, McKee KY, Kohlwes RJ. Efficacy and safety of tunneled pleural catheters in adults with malignant pleural effusions: a systematic review. J Gen Intern Med. 2011;26(1):70–76.
   PubMed Web of Science ®Google Scholar
• Boujaoude Z, Bartter T, Abboud M, et al. Pleuroscopic pleurodesis combined with tunneled pleural catheter for management of malignant pleural effusion: a prospective observational study. J Bronchology Interv Pulmonol. 2015;22(3):237–243.
   PubMedGoogle Scholar
• Ahmed L, Ip H, Rao D, et al. Talc pleurodesis through indwelling pleural catheters for malignant pleural effusions: retrospective case series of a novel clinical pathway. Chest. 2014;146(6):e190–194.
   PubMed Web of Science ®Google Scholar
• Tremblay A, Dumitriu S, Stather DR, et al. Use of a drug eluting pleural catheter for pleurodesis. Exp Lung Res. 2012;38(9–10):475–482.
   PubMed Web of Science ®Google Scholar
• Bhatnagar R, Zahan-Evans N, Kearney C, et al. The SEAL-MPE Trial: A phase I safety evaluation of a novel silver nitrate coated indwelling pleural catheter. Am J Respir Crit Care Med. 2016;193:A7813.
   Web of Science ®Google Scholar
• Detterbeck FC, Nicholson AG, Franklin WA, et al. IASLC staging and prognostic factors committee; advisory boards; multiple pulmonary sites workgroup; participating institutions. the iaslc lung cancer staging project: summary of proposals for revisions of the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming eighth edition of the TNM classification. J Thorac Oncol. 2016;11(5):639–650.
   PubMed Web of Science ®Google Scholar
• Porcel JM. Malignant pleural effusions because of lung cancer. Curr Opin Pulm Med. 2016;22(4):356–361.
   PubMed Web of Science ®Google Scholar
• Fiorelli A, Santini M. In lung cancer patients where a malignant pleural effusion is found at operation could resection ever still be justified? Interact Cardiovasc Thorac Surg. 2013;17(2):407–412.
   PubMed Web of Science ®Google Scholar
• Iida T, Shiba M, Yoshino I, et al. Japanese joint committee of lung cancer registry. Surgical intervention for non-small-cell lung cancer patients with pleural carcinomatosis: results from the Japanese lung cancer registry in 2004. J Thorac Oncol. 2015;10(7):1076–1082.
   PubMed Web of Science ®Google Scholar
• Okamoto T, Iwata T, Mizobuchi T, et al. Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy. Eur J Cardiothorac Surg. 2012;41(1):25–30.
   PubMed Web of Science ®Google Scholar
• Ren Y-J, She Y-L, Dai C-Y, et al. Primary tumour resection showed survival benefits for non-small-cell lung cancers with unexpected malignant pleural dissemination. Interact Cardiovasc Thorac Surg. 2016;22(3):321–326.
   PubMed Web of Science ®Google Scholar
• Yun JK, Kim MA, Choi CM, et al. Surgical outcomes after pulmonary resection for non-small cell lung cancer with localized pleural seeding first detected during surgery. Thorac Cardiovasc Surg. 2015. DOI:10.1055/s-0035-1564928. [ Epub ahead of print].
   PubMedGoogle Scholar
• Mordant P, Arame A, Foucault C, et al. Surgery for metastatic pleural extension of non-small-cell lung cancer. Eur J Cardiothorac Surg. 2011;40(6):1444–1449.
   PubMed Web of Science ®Google Scholar
• Porcel JM, Diaz JP, Chi DS. Clinical implications of pleural effusions in ovarian cancer. Respirology. 2012;17(7):1060–1067.
   PubMed Web of Science ®Google Scholar
• Eisenkop SM. Thoracoscopy for the management of advanced epithelial ovarian cancer–a preliminary report. Gynecol Oncol. 2002;84(2):315–320.
   PubMed Web of Science ®Google Scholar
• Diaz JP, Abu-Rustum NR, Sonoda Y, et al. Video-assisted thoracic surgery (VATS) evaluation of pleural effusions in patients with newly diagnosed advanced ovarian carcinoma can influence the primary management choice for these patients. Gynecol Oncol. 2010;116(3):483–488.
   PubMed Web of Science ®Google Scholar
• Wolf AS, Flores RM. Current treatment of mesothelioma: extrapleural pneumonectomy versus pleurectomy/decortication. Thorac Surg Clin. 2016;26(3):359–375.
   PubMed Web of Science ®Google Scholar
• Treasure T, Lang-Lazdunski L, Waller D, et al. MARS trialists. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12(8):763–772.
   PubMed Web of Science ®Google Scholar
• Rintoul RC, Ritchie AJ, Edwards JG, et al. MesoVATS Collaborators. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet. 2014;384(9948):1118–1127.
   PubMed Web of Science ®Google Scholar
• D’Addario G, Pintilie M, Leighl NB, et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol. 2005;23(13):2926–2936.
   PubMed Web of Science ®Google Scholar
• Kang EJ, Min KH, Hur GY, et al. Comparison of the efficacy between pemetrexed plus platinum and non-pemetrexed plus platinum as first-line treatment in patients with wild-type epidermal growth factor receptor nonsquamous non-small cell lung cancer: a retrospective analysis. Chemotherapy. 2016;61(1):41–50.
   PubMed Web of Science ®Google Scholar
• Masago K, Fujimoto D, Fujita S, et al. Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer. Mol Clin Oncol. 2015;3(2):415–419.
   PubMedGoogle Scholar
• Park K, Yu CJ, Kim SW, et al. First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer: the ASPIRATION study. JAMA Oncol. 2016;2(3):305–312.
   PubMed Web of Science ®Google Scholar
• Park K, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17(5):577–589.
   PubMed Web of Science ®Google Scholar
• Verma A, Chopra A, Lee YW, et al. Can EGFR-tyrosine kinase inhibitors (TKI) alone without talc pleurodesis prevent recurrence of malignant pleural effusion (MPE) in lung adenocarcinoma? Curr Drug Discov Technol. 2016;13(2):68–76.
   PubMedGoogle Scholar
• Han HS, Eom DW, Kim JH, et al. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases. Clin Lung Cancer. 2011;12(6):380–386.
   PubMed Web of Science ®Google Scholar
• Wu SG, Yu CJ, Tsai MF, et al. Survival of lung adenocarcinoma patients with malignant pleural effusion. Eur Respir J. 2013;41(6):1409–1418.
   PubMed Web of Science ®Google Scholar
• Smits AJ, Kummer JA, Hinrichs JW, et al. EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma. Cell Oncol (Dordr). 2012;35(3):189–196.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247–4253.
   PubMed Web of Science ®Google Scholar
• Wu SG, Kuo YW, Chang YL, et al. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. J Thorac Oncol. 2012;7(1):98–104.
   PubMed Web of Science ®Google Scholar
• Agalioti T, Giannou AD, Stathopoulos GT. Pleural involvement in lung cancer. J Thorac Dis. 2015;7(6):1021–1030.
   PubMed Web of Science ®Google Scholar
• Lin JB, Lai FC, Li X, et al. Sequential treatment strategy for malignant pleural effusion in non-small cell lung cancer with the activated epithelial grow factor receptor mutation. J Drug Target. 2016;29:1–6.
   Google Scholar
• Clive AO, Taylor H, Dobson L, et al. Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial. Lancet Oncol. 2016;17(8):1094–1104.
   PubMed Web of Science ®Google Scholar
• Hallifax RJ, Corcoran JP, Psallidas I, et al. Medical thoracoscopy: survey of current practice-how successful are medical thoracoscopists at predicting malignancy? Respirology. 2016;21(5):958–960.
   PubMed Web of Science ®Google Scholar
• Porfyridis I, Georgiadis G, Michael M, et al. Rapid on-site evaluation with the hemacolor rapid staining method of medical thoracoscopy biopsy specimens for the management of pleural disease. Respirology. 2016;21(6):1106–1112.
   PubMed Web of Science ®Google Scholar
• Bielsa S, Martín-Juan J, Porcel JM, et al. Diagnostic and prognostic implications of pleural adhesions in malignant effusions. J Thorac Oncol. 2008;3(11):1251–1256.
   PubMed Web of Science ®Google Scholar
• Saydam O, Karapinar K, Gokce M, et al. The palliative treatment with intrapleural streptokinase in patients with multiloculated malignant pleural effusion: a double-blind, placebo-controlled, randomized study. Med Oncol. 2015;32(6):612.
   PubMed Web of Science ®Google Scholar
• Mishra EK, Clive AO, Wills G, et al. The third therapeutic intervention in malignant effusion trial (TIME3): a randomised controlled trial to assess dyspnea relief and pleurodesis success following intrapleural urokinase in patients with non-draining malignant pleural effusion. American Thoracic Society International Conference 2016. 2016. Abstract D110:A7937.
   Google Scholar
• Thomas R, Azzopardi M, Muruganandan S, et al. Protocol of the PLeural Effusion And Symptom Evaluation (PLEASE) study on the pathophysiology of breathlessness in patients with symptomatic pleural effusions. BMJ Open. 2016;6(8):e013213.
   PubMed Web of Science ®Google Scholar
• Bhatnagar R, Laskawiec-Szkonter M, Piotrowska HE, et al. Evaluating the efficacy of thoracoscopy and talc poudrage versus pleurodesis using talc slurry (TAPPS trial): protocol of an open-label randomised controlled trial. BMJ Open. 2014;4(11):e007045.
   PubMed Web of Science ®Google Scholar
• Fysh ET, Thomas R, Read CA, et al. Protocol of the Australasian Malignant Pleural Effusion (AMPLE) trial: a multicentre randomised study comparing indwelling pleural catheter versus talc pleurodesis. BMJ Open. 2014;4(11):e006757.
   PubMed Web of Science ®Google Scholar
• Azzopardi M, Thomas R, Muruganandan S, et al. Protocol of the Australasian Malignant Pleural Effusion-2 (AMPLE-2) trial: a multicentre randomised study of aggressive versus symptom-guided drainage via indwelling pleural catheters. BMJ Open. 2016;6(7):e011480.
   PubMed Web of Science ®Google Scholar
• Wahidi MM, Reddy C, Yarmus L, et al. Randomized trial of pleural fluid drainage frequency in patients with malignant pleural effusions-The ASAP Trial. Am J Respir Crit Care Med. 2016 Nov 29. DOI:10.1016/j.chest.2017.01.024. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Sivakumar P, Douiri A, West A, et al. OPTIMUM: a protocol for a multicentre randomised controlled trial comparing out patient talc slurry via indwelling pleural catheter for malignant pleural effusion vs usual inpatient management. BMJ Open. 2016;6(10):e012795.
   PubMed Web of Science ®Google Scholar
• Bhatnagar R, Kahan BC, Morley AJ, et al. The efficacy of indwelling pleural catheter placement versus placement plus talc sclerosant in patients with malignant pleural effusions managed exclusively as outpatients (IPC-PLUS): study protocol for a randomised controlled trial. Trials. 2015;16:48.
   PubMed Web of Science ®Google Scholar
• A clinical study evaluating the safety and effectiveness of a new pleural catether for the medical management of symptomatic, recurrent, malignant pleural effusions compared to approved pleural catheter (SWIFT). ClinicalTrials.gov identifier: NCT02649894.
   Google Scholar